BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 06, 2009
 |  BioCentury  |  Product Development

Amira's lipid love affair

Spurred by academic research linking LPA1 to idiopathic pulmonary fibrosis, Amira Pharmaceuticals Inc. used its medicinal chemistry expertise in bioactive lipids to design antagonists for preclinical studies. The company presented proof-of-concept data in a mouse model of IPF last week and hopes to enter the clinic next year with the first candidate it could take to market on its own.

Lysophosphatidic acid (LPA) is an anionic bioactive lipid that acts through EDG receptors to mediate cell proliferation, platelet aggregation, smooth muscle contraction, inhibition of neuroblastoma cell differentiation, chemotaxis and tumor cell invasion. LPA also elicits angiogenesis (see BioCentury, April 13).

Lysophosphatidic acid receptor 1 (LPAR1; EDG2; LPA1) is an EDG receptor that is part of the phosphatidic acid/lysophosphatidylcholine pathway.

In January 2008, researchers from Harvard Medical...

Read the full 636 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >